Aerocrine Inc, New York, wholly owned subsidiary of Aerocrine AB, Sweden, has relocated their technical services and logistics complex to New Providence, NJ. Aerocrine was assisted in the move by local industrial property locators Staubach, and property managers, David Cronheim Co.
“This facility will give us the space we need to better service our rapidly growing customers base,” said Trevor Bourke, Aerocrine Inc president. “Asthma is an increasing health care problem today affecting 30 million Americans. NIOX®, Aerocrine’s lead product is the first device available for routine clinical monitoring of inflammation in the airways of asthma patients. By measuring airway inflammation, the main pathogenic factor in asthma, NIOX helps doctors monitor and treat asthma patients more accurately in a range of clinical settings.”
Aerocrine is dedicated to improving the management and care of patients through measurement of airborne markers, primarily nitric oxide as an effective and reliable method for the diagnosis and ongoing control of diseases.